Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: General Crude who wrote (4425)	6/3/1998 3:00:00 PM
From: Intel Trader	Respond to of 6136

interactive.wsj.com!WJ05/07+++123!BT05/06++4678!BT05/06++2822!WJ05/06+++207!WJ05/06++++60!BT05/05++1960!BT05/05++1695!BT04/16++3751!BT04/15++3922!WJ04/15++++24!BT04/15++++40!BT04/14++5761!BT04/14++4620!BT04/13++2196!WJ04/09++++76!WJ03/26++++63!BT03/06++1324!&time=06/03+13:48 Dow Jones Newswires -- June 3, 1998 Agouron Sees NDA For AG3340 Cancer Drug In 2000 NEW YORK (Dow Jones)--Agouron Pharmaceuticals Inc. (AGPH) hopes to file a new drug application with the Food and Drug Administration in 2000 for its AG3340 compound to treat cancer, according to President and Chief Executive Peter Johnson. AG3340 has been shown to inhibit tumor growth in laboratory animals. The compound works by inhibiting the growth of matrix metalloproteases, or MMPs, a family of enzymes that has been linked to the growth and spread of cancer cells. AG3340 is being studied in Phase III clinical trials to evaluate its effect against non-small cell lung cancer and hormone-refractory prostate cancer in combination with other cancer drugs. Speaking here at the PaineWebber Growth & Technology Conference, Johnson said Agouron also hopes to submit an NDA for AG3340 for the treatment of age-related macular degeneration about six months after its cancer filing, Johnson said. Agouron's protease inhibitor Viracept should overtake Merck & Co.'s (MRK) Crixivan within the "next several months" to become the most prescribed protease inhibitor in the U.S., Johnson said. Viracept has enjoyed a very strong sales ramp-up since the FDA approved the drug in March 1997. As of March 31, the drug had racked up sales of more than $308 million. Johnson said the sales growth potential for Viracept remains bright. Of the approximately 900,000 Americans who were believed to be HIV-positive in April, about 30% were not diagnosed, while another 30% were diagnosed but were not receiving treatment, Johnson said. He also noted that competition among different protease inhibitors isn't strictly a zero-sum game, considering that combination therapies are becoming more common. Of all patients currently being treated with protease inhibitors, it is believed that about 10% to 15% are taking two in combination, he said. That percentage is expected to double during the next year, he added. - Louis Hau; 201-938-5240 Powered by Quote Agentr and News Agentr from Gari Software/IDD Information Services Copyright c 1998 Dow Jones & Company, Inc. All Rights Reserved.

To: General Crude who wrote (4425)	6/3/1998 8:00:00 PM
From: Intel Trader	Read Replies (2) \| Respond to of 6136

Here I go talking to myself again : ) As for the news regarding AGPH and its impending FDA approval over a year hence, ok -- so far, so good. I'm in at 34 1/2 today. I'm comfortable that AGPH has shown rather good relative strength over about the last 6 weeks under current market conditions. That is not to say that the market couldn't/wouldn't cause Agouron some damage, but if there is damage, it can and will be overcome. Cheers to all, and lets see if we can enliven the conversation here a bit. it